Plain-English translation of NCT07227818 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether , a new medication, can help keep schizophrenia symptoms from returning in adults whose condition is currently stable. Everyone in the study first receives the medication to see how well they respond. Then, some participants will continue taking it while others will unknowingly switch to a placebo (a pill with no active ingredient) to see if the medication truly helps prevent relapse.
For many people with schizophrenia, staying on medication is the best way to prevent symptoms from flaring up again, but current treatments don't work equally well for everyone. This study is trying to find out whether this new treatment is more effective than placebo at keeping people stable long-term.
You likely qualify if…
You likely don't qualify if…
First, you will take the new medication for several weeks during a stabilization period so doctors can see how you respond. If you respond well, you will then be randomly assigned to either continue the medication or switch to a placebo for the main part of the study. Throughout this time, you will have regular visits to a research clinic where your symptoms and overall health will be monitored.
AI-generated summary from trial data · Jun 29, 2026 · Not medical advice
United States